Lilly presents durable first-line activity of olomorasib in KRAS G12C-mutant NSCLC at ESMO 2026
Lilly reported that olomorasib plus pembrolizumab without chemotherapy achieved durable efficacy, with median progression-free survival not yet reached after a median follow-up of 20.7 months. In a separate rapid oral presentation, the combination with chemoimmunotherapy yielded a 62% investigator-assessed overall response rate and a median duration of response of 14.5 months.
Primary source
Company press release (PR Newswire), October 25, 2026
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Machine-summarized from the source above; not independently reported. How we use automation